Cambrex Corporation Just Recorded A Sigfniciant Bullish Options Activity

 Cambrex Corporation Just Recorded A Sigfniciant Bullish Options Activity

In today’s session Cambrex Corporation (CBM) registered an unusually high (284) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the April, 2017 call, expecting serious CBM increase. With 284 contracts traded and 134 open interest for the Apr, 17 contract, it seems this is a quite bullish bet. The option with symbol: CBM170421C00055000 closed last at: $1.55 or 13.9% down. About 187,440 shares traded hands. Cambrex Corporation (NYSE:CBM) has risen 9.81% since April 7, 2016 and is uptrending. It has outperformed by 5.03% the S&P500.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

Out of 4 analysts covering Cambrex Corp (NYSE:CBM), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cambrex Corp has been the topic of 4 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Monday, November 7 by First Analysis. Stephens initiated Cambrex Corporation (NYSE:CBM) rating on Tuesday, July 21. Stephens has “Overweight” rating and $55 price target. The stock of Cambrex Corporation (NYSE:CBM) has “Buy” rating given on Thursday, February 11 by Singular Research.

According to Zacks Investment Research, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems.”

Insitutional Activity: The institutional sentiment increased to 1.03 in 2016 Q2. Its up 0.34, from 0.69 in 2016Q1. The ratio increased, as 22 funds sold all Cambrex Corporation shares owned while 76 reduced positions. 31 funds bought stakes while 70 increased positions. They now own 28.84 million shares or 4.08% less from 30.07 million shares in 2016Q1.
Arizona State Retirement Systems owns 16,576 shares or 0.01% of their US portfolio. The Florida-based Independent Portfolio Consultants has invested 0% in Cambrex Corporation (NYSE:CBM). Diam Com has 80,075 shares for 0.06% of their US portfolio. Renaissance Ltd Liability Company holds 0% of its portfolio in Cambrex Corporation (NYSE:CBM) for 34,300 shares. Ls Invest Advsr Ltd last reported 1,327 shares in the company. Icon Advisers holds 6,200 shares or 0.02% of its portfolio. Oxford Asset Management accumulated 126,148 shares or 0.27% of the stock. Deere & last reported 0.02% of its portfolio in the stock. New York State Common Retirement Fund has invested 0.01% of its portfolio in Cambrex Corporation (NYSE:CBM). Boston Advsrs Limited Liability Corp accumulated 0.01% or 11,272 shares. Gemmer Asset Mgmt Ltd Limited Liability Company reported 117 shares or 0% of all its holdings. Systematic Fincl L P owns 37,929 shares or 0.03% of their US portfolio. Bridgeway Capital Mngmt Inc holds 10,650 shares or 0.01% of its portfolio. Alps has 0% invested in the company for 9,844 shares. Deroy & Devereaux Private Inv Counsel, a Michigan-based fund reported 33,700 shares.

Insider Transactions: Since June 8, 2016, the stock had 0 insider purchases, and 2 selling transactions for $405,431 net activity. KORB WILLIAM B had sold 3,420 shares worth $188,100 on Monday, July 11.

Cambrex Corporation is a life sciences company. The company has a market cap of $1.71 billion. The Firm provides services and products for the development and commercialization of new and generic therapeutics. It has a 25.15 P/E ratio. The Firm supplies its services and products across the world to generic pharmaceutical companies.

CBM Company Profile

Cambrex Corporation (Cambrex), incorporated on October 11, 1983, is a life sciences company. The Firm provides services and products for the development and commercialization of new and generic therapeutics. The Firm supplies its services and products across the world to generic pharmaceutical companies. Cambrex operates through three divisions, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States.

More important recent Cambrex Corporation (NYSE:CBM) news were published by: Fool.com which released: “Pharma Manufacturer Cambrex Corporation Rose as Much as 19.3% on Strong Earnings” on November 04, 2016, also Seekingalpha.com published article titled: “Cambrex Corporation: Exciting Time Ahead For This Biotech Company”, Fool.com published: “Why Cambrex Corporation Earned a Higher Share Price Today” on February 09, 2016. More interesting news about Cambrex Corporation (NYSE:CBM) was released by: Globenewswire.com and their article: “Claes Glassell Appointed to the Board of Directors of Cambrex Corporation” with publication date: March 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment